FY2025 · ended Dec 31, 2025 · Revenue $1.86B, +4.3% YoY · Filed Mar 2, 2026
Sarepta Therapeutics, Inc. (SRPT) files with the SEC under industry code 2834, Pharmaceutical Preparations. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.9 billion and a net loss of $713.4 million. Free cash flow was -$307.5 million. As of Jun 30, 2026 it held $933.9 million in cash and investments and $1.0 billion in total debt.
Revenue (TTM)
$1.40B
-36.2% vs year-ago TTM
Net income (TTM)
$-136.72M
-135.9% vs year-ago TTM
Operating cash flow (TTM)
$111.01M
+136.9% vs year-ago TTM
Free cash flow (TTM)
$81.85M
+118.1% vs year-ago TTM
EPS (TTM)
$-1.22
-125.2% vs year-ago TTM
Dividend per share
None
Shares outstanding
104.99M
+8.2% vs prior year
Net cash
$-111.99M
as of Jun 30, 2026
Operating margin
-10.2%
FY 2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- SRPT (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 873303
- Former names
- Sarepta Therapeutics, Inc. (until Sep 23, 2026); AVI BIOPHARMA INC (until Jul 12, 2012); ANTIVIRALS INC (until May 12, 1998)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.9B | $1.8B | $1.1B | $843.8M | $612.4M |
| Operating income | -$699.8M | $218.1M | -$267.8M | -$536.2M | -$459.7M |
| Net income | -$713.4M | $235.2M | -$536.0M | -$703.5M | -$418.8M |
| Diluted EPS | -$7.13 | $2.34 | -$5.80 | -$8.03 | — |
| Operating cash flow | -$205.5M | -$205.8M | -$501.0M | -$325.3M | -$443.2M |
| Free cash flow | -$307.5M | -$342.7M | -$577.1M | -$356.2M | -$481.7M |
| Total assets | $3.3B | $4.0B | $3.3B | $3.1B | $3.1B |
| Total liabilities | $2.2B | $2.4B | $2.4B | $2.7B | $2.2B |
| Stockholders' equity | $1.1B | $1.5B | $859.3M | $384.9M | $928.0M |
| Cash and investments | $940.7M | $1.5B | $2.1B | $2.0B | $2.1B |
| Total debt | $1.0B | $1.3B | $1.4B | $1.6B | $56.6M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Sep 23, 2026 | Sep 23, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 5, 2026 | Aug 5, 2026 |
| 10-Q | Quarterly report | Aug 5, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jul 27, 2026 | Jul 23, 2026 |
| 8-K |
Current report
Officer or director change, Shareholder vote results
|
Jun 4, 2026 | Jun 4, 2026 |
| 8-K |
Current report
Results of operations
|
May 6, 2026 | May 6, 2026 |
All 1000 Sarepta Therapeutics, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.